紫癜性肾炎患儿血清PTX3、IgA/C3水平变化及与肾功能损伤的相关性

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (688 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the changes of serum pentamerin-3 (PTX3) and IgA/C3 levels in patients with purpuric nephritis and their correlations with renal damage. Methods The 96 patients with purpuric nephritis treated with mycophenolate mofetil combined with prednisone treated in our hospital between May 2014 and June 2019 were selected as the treatment group while another 80 healthy physical examinees in the same period were selected as the control group. The changes of serum levels of immunoglobulin A (IgA), immunoglobulin G (IgG), immunoglobulin M (IgM), complement C3 (C3) and PTX3 in the two groups were observed. The IgA/C3 value was calculated, while the difference in serum IgA/C3 levels and renal function indexes was compared between the two groups. The Pearson method was used to analyze the correlations between serum PTX3, IgA/C3 levels and renal impairment in patients with purpuric nephritis treated with mycophenolate mofetil combined with prednisone. Results Serum levels of IgA, PTX3, IgA/C3, and SCr in the treatment group were significantly higher than those of the control group, but serum IgG, IgM, eGFR, and α-MG levels were significantly lower (P<0.05). Pearson correlation analysis showed that serum IgA/C3 and PTX3 levels were positively correlated with serum SCr levels, but negatively with serum eGFR and α-MG levels (P<0.05). Conclusions After combined treatment with mycophenolate mofetil and prednisone, the serum PTX3 and IgA/C3 levels of patients with purpuric nephritis have been improved to some extent, and they are positively correlated with renal function damage.

Key words： mycophenolate mofetil combined with prednisone purpuric nephritis PTX3 IgA/C3 renal function correlation

Received: 10 August 2020

ZTFLH:

R556.6

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHOU Bin
	DANG Xiaoning
	FU Zhongguo
	CAO haini
	YANG Lihong

Cite this article:

ZHOU Bin,DANG Xiaoning,FU Zhongguo等. Changes of serum PTX3 and IgA/C3 levels in patients with Henoch Schonlein purpura nephritis treated with mycophenolate mofetil and prednisone[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2021, 32(3): 193-196.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2021/V32/I3/193

[1]	Hiroyuki T, Hiroshi M. Henoch schönlein purpura nephritis associated with intravesical bacillus calmette-guerin (bcg) therapy[J]. Intern Med, 2017, 56(5):541-544.
[2]	赵慧, 殷健. 消化道穿孔为主要表现的过敏性紫癜1例[J]. 武警医学, 2019, 30(1):70-71.
[3]	杜川,董璇,陈铖,等.儿童紫癜性肾炎244例的流行病学特征与肾脏受累危险因素分析[J].西部医学,2017,29(9):1268-1271.
[4]	邢静, 李文斌, 王艳飞,等. 儿童过敏性紫癜血清IL-21、TGF-β1、TNF-α、IgA1的变化与紫癜性肾炎发生的相关性研究[J]. 基因组学与应用生物学, 2017,20(7):2633-2639.
[5]	李锦芬,李晓忠.血清胱抑素C纤维蛋白原及24小时尿蛋白定量对紫癜性肾炎儿童肾损伤程度的评估效果[J].安徽医学,2018,39(2):186-188.
[6]	Jean D D, Julien H, Bilal A, et al. Clinical outcomes in children with henoch-sch?nlein purpura nephritis without crescents[J]. Pediatr Nephrol, 2017, 32(7):1193-1199.
[7]	朱春华, 黄松明. 紫癜性肾炎诊治循证指南(2016)解读[J]. 中华儿科杂志, 2017, 55(9):654-657.
[8]	Kasahara K, Gotoh Y, Kuroyanagi Y, et al.Warfarin-induced toxic epidermal necrolysis in combination therapy of henoch-sch nlein purpura nephritis: a case report[J]. Bmc Nephrol, 18(1):237-245.
[9]	Zhao S, Shen H, Gu W, et al. Evaluation of TGF-β1 and MCP-1 expression and tubulointerstitial fibrosis in children with Henoch-Schönlein purpura nephritis and IgA nephropathy: a clinical correlation[J]. Clinics, 2017, 72(2):95-102.
[10]	Huang Xiao, Wu Xiaomei, Le Weibo, et al. Renal prognosis and related risk factors for henoch-schnlein purpura nephritis: a chinese adult patient cohort[J]. Sci Rep, 2001,8(1):5585-5596.
[11]	Wang J, Li Y, Chen Y, et al. Urinary macrophage migration inhibitory factor as a noninvasive biomarker in pediatric henoch-schnlein purpura nephritis[J]. J Clin Rheumatol, 2001,23(5):258-261.
[12]	Deng Z, Yang Z, Ma X, et al. Urinary metal and metalloid biomarker study of Henoch-Schonlein purpura nephritis using inductively coupled plasma orthogonal acceleration time-of-flight mass spectrometry[J]. Talanta, 2018, 178(6):728-735.
[13]	姜维. 泼尼松联合吗替麦考酚酯治疗对难治性肾病综合征患者细胞免疫功能及细胞因子的影响[J]. 中国医师杂志,2017,19(5): 742-744.
[14]	张建江, 贾莉敏, 史佩佩,等. 吗替麦考酚酯联合糖皮质激素治疗儿童紫癜性肾炎的疗效观察[J]. 中华肾脏病杂志, 2017, 33(9):670-677.
[15]	Sedhain A, Hada R, Agrawal R K, et al. Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial[J]. Bmc Nephrol, 2018,19(1):175-183.
[16]	刘梅, 王军, 孙红, 等. 过敏性紫癜与紫癜性肾炎患儿免疫功能的比较及临床意义探讨[J]. 检验医学与临床, 2019,16(8):58-61.
[17]	Min Tan, Jing Fang, Qianqian Xu, et al. Outcomes of normotensive IgA nephropathy patients with mild proteinuria who have impaired renal function[J]. Renal Failure, 2019, 41(1):875-882.
[18]	Yuan M, Tan Y, Pang Y, et al. Anti-pentraxin 3 auto-antibodies might be protective in lupus nephritis: a large cohort study[J]. Ren Fail, 2017, 39(1):465-473.

[1]	. [J]. Med. J. Chin. Peop. Armed Poli. Forc., 2021, 32(4): 362-364.